Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)
Completed
Merck Sharp & Dohme Corp.
2008-03-01
The purpose of this study is to collect information on unexpected adverse reactions (ADRs),
how often ADRs occur, and factors that can affect the safety and effectiveness of Claritin
(loratadine) when used in children. Patients will be observed while they are taking Claritin,
and ADRs and symptom scores will be recorded. At the end of treatment, improvement in
symptoms will be recorded.
Post-marketing surveys are not considered applicable clinical trials and thus the results of
this survey will not be posted at its conclusion. The results will be submitted to public
health officials as required by applicable national and international laws.
Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions
Completed
Ranbaxy Laboratories Limited
N/A
2006-06-01
To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating
tablets of Ohm Laboratories (a subsidiary of Ranbaxy Pharmaceuticals Inc., USA) with
Claritin® Reditabs® (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc.,
USA in healthy, adult, human male subjects under fasting condition.
Bioequivalence Study of Loratadine Orally Disintegrating Tablets 10 mg Under Fed Conditions
Completed
Ranbaxy Laboratories Limited
N/A
2006-07-01
To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating
tablets of Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, Inc. USA) with
Claritin® Reditabs® (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc.,
USA in healthy, adult, human male subjects under fed condition.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
